Betamethasone dipropionate - CAS 5593-20-4
Catalog number: 5593-20-4
Category: Inhibitor
Not Intended for Therapeutic Use. For research use only.
COA:
Inquire
Description:
Glucocorticoid. Used as anti-inflammatory and antibacterial ointment for dermatosis.
Publictions citing BOC Sciences Products
  • >> More
Purity:
0.98
Appearance:
white solid
Synonyms:
Alphatrex; Beta-Val; Diprolene; Diprolene AF; Diprosone; Luxiq
MSDS:
Inquire
1.Topical calcipotriol/betamethasone dipropionate for psoriasis vulgaris: A systematic review.
Yan R1, Jiang S, Wu Y, Gao XH, Chen HD. Indian J Dermatol Venereol Leprol. 2016 Feb 8. doi: 10.4103/0378-6323.175919. [Epub ahead of print]
Topical calcipotriol/betamethasone dipropionate ointment/gel has been commonly used for the treatment of psoriasis vulgaris. However, the efficacy of this combination needs to be consolidated. To assess the effects and safety profile of calcipotriol/betamethasone dipropionate for the treatment of psoriasis vulgaris, using evidence based approach. Randomized controlled trials on the treatment of psoriasis vulgaris with calcipotriol/betamethasone dipropionate were identified by searching PubMed, China National Knowledge Infrastructure and the Cochrane Library. The primary outcome measure was the Psoriasis Area and Severity Index (PASI) score. Ten randomized controlled trials involving 6590 participants were included. The methodologies of the studies were generally of moderate to high quality. These trials used topical calcipotriol/betamethasone dipropionate for 4 or 8 weeks, and were compared with topical calcipotriol or betamethasone. The results showed that calcipotriol/betamethasone dipropionate was more effective than controls.
2.Calcipotriene and Betamethasone Dipropionate for the Topical Treatment of Plaque Psoriasis.
Kin KC1, Hill D2, Feldman SR2,3,4. Expert Rev Clin Pharmacol. 2016 Apr 19. [Epub ahead of print]
Psoriasis affects an estimated 2% of the world's population, with higher rates in developed countries. 80% have mild-to-moderate disease and 50 to 80% have scalp involvement. Topical treatments are the mainstay of treatment. Two-compound calcipotriene and betamethasone dipropionate is a common topical combination therapy consisting of a vitamin D analogue and a corticosteroid. It comes in ointment, gel/suspension, and foam formulations. Phase II and III clinical trials have consistently shown the two-compound formulation to be more effective and safer than the individual ingredients in the same vehicle for treating body and scalp psoriasis. No clinically significant skin atrophy, calcium level changes, or adrenal suppression were seen. Topical scalp solution was also safe and effective in treating scalp psoriasis in pediatric populations. Calcipotriene plus betamethasone dipropionate should be considered a first line therapy for mild-to-moderate plaque psoriasis.
3.Topical calcipotriol/betamethasone dipropionate for psoriasis vulgaris: A systematic review.
Yan R, Jiang S, Wu Y1, Gao XH, Chen HD. Indian J Dermatol Venereol Leprol. 2016 Mar-Apr;82(2):135-44. doi: 10.4103/0378-6323.175919.
Topical calcipotriol/betamethasone dipropionate ointment/gel has been commonly used for the treatment of psoriasis vulgaris. However, the efficacy of this combination needs to be consolidated. We aimed to assess the effects and safety profile of calcipotriol/betamethasone dipropionate for the treatment of psoriasis vulgaris, using evidence based approach. Randomized controlled trials on the treatment of psoriasis vulgaris with calcipotriol/betamethasone dipropionate were identified by searching PubMed, China National Knowledge Infrastructure and the Cochrane Library. The primary outcome measure was the Psoriasis Area and Severity Index (PASI) score. Ten randomized controlled trials involving 6590 participants were included. The methodologies of the studies were generally of moderate to high quality. These trials used topical calcipotriol/betamethasone dipropionate for 4 or 8 weeks, and were compared with topical calcipotriol or betamethasone.
4.Improvement in Extensive Moderate Plaque Psoriasis With a Novel Emollient Spray Formulation of Betamethasone Dipropionate 0.05.
Stein Gold L, Jackson JM, Knuckles ML, Weiss JS. J Drugs Dermatol. 2016 Mar 1;15(3):334-42.
BACKGROUND: A novel formulation of 0.05% betamethasone dipropionate in an emollient spray vehicle (DFD-01) was developed to deliver steroid to the skin layers most affected by psoriasis.<br/>
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Chemical Structure

CAS 5593-20-4 Betamethasone dipropionate

Quick Inquiry

Verification code

Featured Items